Latest News and Press Releases

DURHAM, N.C., July 07, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...

-- HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of peripheral arterial disease, arteriovenous access for hemodialysis, and trauma – --...

DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...

-- Successful first two HAV implantations in wounded Ukrainian citizens -- HAVs were provided under Humacyte’s initiative to assist Ukraine humanitarian medical effort -- Provides further real-world...

-- Data indicate HAV does not stimulate increase in panel reactive antibodies, an adaptive immune response correlated with increased risk of implant failure -- -- Data presented today in IMPACT...

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...

-- Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries -- -- Strengthened leadership team with appointment of Shamik...

-- First shipment of HAVs to six Ukrainian hospitals made today -- -- Product candidate to be used for civilian and military vascular trauma repair, the HAV’s lead investigational indication -- ...

DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...

--Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle-- --Key appointment as Humacyte advances HAV through...